Key result
A history of hypertension for ≥5 years was associated with 0.42 SD higher serum endostatin compared with normotensives (95% CI 0.23-0.61; P<0.001), correlating with target-organ damage.
Why the study?
Is circulating endostatin associated with hypertension duration and hypertensive target-organ damage in older adults?
Cohort (n=1,597)
Is circulating endostatin associated with hypertension duration and hypertensive target-organ damage in older adults?
Circulating endostatin is significantly elevated in individuals with long-standing hypertension and correlates with vascular, myocardial, and renal indices of target-organ damage.
Answers are grounded in this paper and cite their sources.
Does not support routine endostatin measurement; leaves open its prognostic value in chronic hypertension pending prospective studies.
Our aim is to study associations between circulating endostatin, hypertension duration, and hypertensive target-organ damage. Long-term hypertension induces cardiovascular and renal remodeling. Circulating endostatin, a biologically active derivate of collagen XVIII, has been suggested to be a relevant marker for extracellular matrix turnover and remodeling in various diseases. However, the role of endostatin in hypertension and hypertensive target-organ damage is unclear. Serum endostatin was measured in 2 independent community-based cohorts: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; women 51%; n = 812; mean age, 75 years) and the Uppsala Longitudinal Study of Adult Men (ULSAM; n=785; mean age, 77.6 years). Retrospective data on blood pressure measurements and antihypertensive medication (PIVUS >5 years, ULSAM >27 years), and cross-sectional data on echocardiographic left ventricular mass, endothelial function (endothelium-dependent vasodilation assessed by the invasive forearm model), and urinary albumin/creatinine ratio were available. In PIVUS, participants with ≥ 5 years of history of hypertension portrayed 0.42 SD (95% confidence interval, 0.23-0.61; P<0.001) higher serum endostatin, compared with that of normotensives. This association was replicated in ULSAM, in which participants with 27 years hypertension duration had the highest endostatin (0.57 SD higher; 95% confidence interval, 0.35-0.80; P<0.001). In addition, higher endostatin was associated with higher left ventricular mass, worsened endothelial function, and higher urinary albumin/creatinine ratio (P<0.03 for all) in participants with prevalent hypertension. Circulating endostatin is associated with the duration of hypertension, and vascular, myocardial, and renal indices of hypertensive target-organ damage. Further studies are warranted to assess the prognostic role of endostatin in individuals with hypertension.
No takes yet. Share an insight, caveat, or question.
Carlsson et al. (2013) conducted a cohort in Hypertension and hypertensive target-organ damage (n=1,597). Hypertension duration vs. Normotensives was evaluated on Serum endostatin levels (0.42 SD higher, 95% CI 0.23-0.61, p=<0.001). A history of hypertension for ≥5 years was associated with 0.42 SD higher serum endostatin compared with normotensives (95% CI 0.23-0.61; P<0.001), correlating with target-organ damage.
Synapse has enriched 10 related papers. Consider them for comparative context: